QUESTIONS ON THE PRESENTATION

"Pharmacokinetics of Antidepressants" (11-01-15). Select the single best choice.

1. Some SSRIs are clinically relevant inhibitors of some CYPs.

    A. True

    B. False

2. Bupropion has some relevant pharmacokinetic characteristics:

    A. It is metabolized by CYP2B6.

    B. It is a moderate CYP2D6 inhibitor.

    C. It is extremely sensitive to induction.

    D. All of the above are correct.

3. CYP2C19 is important for the metabolism of:

    A. Amitriptyline, clomipramine and desipramine.

    B. Amitriptyline, nortriptyline and imipramine.

    C. Amitriptyline, clomipramine and imipramine.

    D. Desipramine, clomipramine and imipramine.

4. Norfluoxetine contributes to CYP inhibition and can remain in the body for months after fluoxetine discontinuation.

    A. True

    B. False

5. Correct pairs of parent drugs and metabolites include:

    A. Amitriptyline/nortriptyline, clomipramine/nortriptyline and imipramine/desipramine.

    B. Amitriptyline/nortriptyline, clomipramine/none and imipramine/desipramine.

    C. Amitriptyline/nortriptyline, clomipramine/desmethylclomipramine and imipramine/desipramine.

    D. Amitriptyline/imipramine, clomipramine/desmethylclomipramine and imipramine/nortriptyline.

6. Fluoxetine and paroxetine inhibit their own metabolism.

    A. True

    B. False

7. CYP2D6 is probably the most important metabolic enzyme for:

    A. Bupropion, fluoxetine, paroxetine, venlafaxine and vortioxetine.

    B. Fluoxetine, paroxetine, desvenlafaxine, venlafaxine and vortioxetine.

    C. Citalopram, paroxetine, desvenlafaxine, venlafaxine and vortioxetine.

    D. Fluoxetine, paroxetine, venlafaxine and vortioxetine.

8. Regarding CYP2D6 inhibition:

    A. Paroxetine and bupropion are potent inhibitors while fluoxetine and duloxetine are moderate.

    B. Paroxetine and fluoxetine are potent inhibitors while bupropion and duloxetine are moderate.

    C. Paroxetine and duloxetine are potent inhibitors while fluoxetine and bupropion are moderate.

    B. Bupropion and duloxetine are potent inhibitors while paroxetine and fluoxetine are moderate.

9. Regarding venlafaxine metabolism:

    A. The CYP2D6 polymorphism may be relevant.

    B. A ratio <1 for O-desmethylvenlafaxine/venlafaxine concentrations is a sign of CYP2D6 poor metabolizer phenotype.

    C. Paroxetine and fluoxetine are clinically relevant inhibitors of its metabolism

    D. All of the above.

10. Fluvoxamine is a potent CYP1A2 and CYP2C19 inhibitor.

    A. True

    B. False